FDA Panel Backs Galleri Blood Test That Misses 69% of Cancers
GRAIL's Galleri test screens 50-plus cancers from one blood draw, but missed 69% of cases and showed no mortality benefit — and an FDA panel backed it anyway.
Topic
Cancer Screening
Topic
Cancer Screening
Grail's Galleri Screens for 50 Cancers. Insurers Won't Pay Yet
Grail's Galleri test screens for 50 cancers from one blood draw, but a major study failed to prove detection of later-stage cance…